cas 56-91-7|| where to buy 4-(Aminomethyl)benzoic acid

Nom du produit:4-(Aminomethyl)benzoic acid

IUPAC Name:4-(aminomethyl)benzoic acid

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM158174-1000g	in stock	ȁŴƙ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 56-91-7 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:56-91-7; Formule moléculaire:C8H9NO2; Point de fusion:-; Code SMILES:C1=C(C=CC(=C1)CN)C(O)=O; Densité:

: Numéro de catalogue:CM158174; Poids moléculaire:151.17; Point d'ébullition:323.1°C at 760 mmHg; N° Mdl:MFCD00010203; Stockage:Protect from light and store in a dry and close container at 2°C~8°C

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Pirtobrutinib; Eli Lilly and Company announced that the U.S. FDA approved Jaypirca® (Pirtobrutinib) for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a Bruton's tyrosine kinase (BTK) inhibitor and a BCL-2 inhibitor. Jaypirca (Pirtobrutinib) is a highly selective (300 times more selective for BTK versus 98% of other kinases tested in preclinical studies), non-covalent (reversible) inhibitor of the enzyme BTK.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.